Table 3.
Proportions of patients with a positive inflammatory gene signature of circulating monocytes prior to therapy measured in total and by response.
| Predominantly serotonergic agents | HC | MDD | Inflammatory negatives | Inflammatory positives | ||
|---|---|---|---|---|---|---|
| Positive | Positive | Responders | Non-responders | Responders | Non-responders | |
| Sertraline plus Placebo (SSRI) | 5/42 (12%) | 7/19 (37%) | 8/12 (67%) | 4/12 (33%) | 5/7 (71%) | 2/7 (29%) |
| Sertraline plus Celecoxib (COX-2 inhibitor) | idem | 3/16 (19%) | 11/13 (85%) | 2/13 (15%) | 2/3 (67%) | 1/3 (33%) |
| Venlafaxine (SNRI) | 2/22 (9%) | 6/14 (43%) | 3/8 (38%) | 5/8 (62%) | 2/6 (33%) | 4/6 (66%) |
| Imipramine (TCA) | 2/23 (9%) | 9/20 (45%) | 4/11 (36%) | 7/11 (64%) | 2/9 (22%) | 7/9 (78%) |
| SUM | 9/87 (10%) | 25/69 (36%)* | 26/44 (59%)* | 18/44 (41%)* | 11/25 (44%)* | 14/25 (56%)* |
SSRI, selective serotonin reuptake inhibitors; SNRI, sertraline–noradrenaline reuptake inhibitors; TCA, tricyclic antidepressant; COX-2, cyclooxygenase 2; HC, healthy controls; MDD, major depressive disorder.
*p ≤ 0.05 compared to HC.
Positivity was defined by an upregulation of 6 (or more) of the 10 cluster 1 genes.
Original Q-PCR data have been uploaded and can be retrieved via the GEO repository ref number GSE132315: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132315